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ABSTRACT

Molecular epidemiology of Clostridium diﬃcile infection (CDI) has been extensively studied in North America and Europe;
however, limited data on CDI are available in the Asia-Paciﬁc region. A multicentre retrospective study was conducted in
this region. C. diﬃcile isolates were subjected to multilocus sequence typing (ST) and antimicrobial susceptibility testing.
Totally, 394 isolates were collected from Hangzhou, Hong Kong, China; Busan, South Korea; Fukuoka, Japan; Singapore;
Perth, Sydney, Australia; New York, the United States. C. diﬃcile isolates included 337 toxin A-positive/B-positive/binary
toxin-negative (A+B+CDT-), 48 A-B+CDT-, and nine A+B+CDT+. Distribution of dominant STs varied geographically with
ST17 in Fukuoka (18.6%), Busan (56.0%), ST2 in Sydney (20.4%), Perth (25.8%). The antimicrobial resistance patterns were
signiﬁcantly diﬀerent among the eight sites (χ 2 = 325.64, p < 0.001). Five major clonal complexes correlated with unique
antimicrobial resistances. Healthcare-associated (HA) CDI was mainly from older patients with more frequent
antimicrobial use and higher A-B+ positive rates. Higher resistance to gatiﬂoxacin, tetracycline, and erythromycin were
observed in HA-CDI patients (χ 2 = 4.76-7.89, p = 0.005-0.029). In conclusion, multiple C. diﬃcile genotypes with varied
antimicrobial resistance patterns have been circulating in the Asia-Paciﬁc region. A-B+ isolates from older patients with
prior antimicrobial use were correlated with HA-CDI.
ARTICLE HISTORY Received 1 August 2019; Revised 13 October 2019; Accepted 14 October 2019
KEYWORDS Clostridium diﬃcile; molecular characteristics; antimicrobial resistance; Asia-Paciﬁc region; healthcare-associated CDI

Introduction
Clostridium diﬃcile is a Gram-positive ubiquitous
endospore-forming anaerobic bacterium that is a leading cause of antimicrobial-associated diarrhea and colitis [1]. C. diﬃcile infection (CDI) is a toxin-mediated
disease, with clinical presentations ranging from mild
self-limiting diarrhea to life-threatening pseudomembranous colitis, toxic megacolon, bowel perforation
and sepsis [2]. While CDI was initially mainly a

healthcare-associated (HA) disease related to advanced
age, exposure to antimicrobials and duration of hospitalization [3–5], there has been an increase in community-associated (CA)- CDI worldwide [6].
Recent global epidemics of CDI have shown that
C. diﬃcile is frequently transmitted between continents[7,8]. The epidemiology of CDI has been well
documented in North America and Europe, particularly the emergence of ribotype (RT) 027 [6,9],
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however, the epidemiology continues to evolve. In
comparison to these published in 2011 [9], data from
2012 to 2014 in Europe showed that the distribution
of the most common RTs has changed and new RTs
have emerged with a wide diversity of genotypes in
diﬀerent countries[10]. According to recent reports
from the United States of America (USA) the proportion of RT 027 decreased signiﬁcantly from 2011
to 2017 with increases of RTs: 106, 002, and 056 [11].
With its large population and expanding economy
over recent decades, Asia has been facing challenges
related to many infectious diseases, including CDI
[12]. The mean overall prevalence of CDI in Asia was
14.8% with a pooled C. diﬃcile incidence density of
5.3/10,000 patient days [13]. A recent prospective
study in Japan found a higher C. diﬃcile incidence density (7.4/10,000 patient days) than that previously
reported [14]. Based on limited data from China, CDI
among hospitalized patients with diarrhea had a pooled
prevalence of 14.0% [15]. However, in general, there is a
paucity of data on CDI in Asia owing to poor awareness
among clinicians and an underestimation of contribution of CDI to antimicrobial-related diseases [12].
The molecular epidemiology of CDI in diﬀerent
regions in Asia is even more poorly understood than
the traditional epidemiological features of the disease.
There have been few studies in recent years with variable
results among diﬀerent countries. In China, C. diﬃcile
isolates with the dominant genotypes of ST2, ST3,
ST35, and ST37 have been shown to be highly resistant
to clindamycin and erythromycin, with high rates of
multidrug resistance [15–17]. In Japan, ST17, which
includes the closely related RTs smz/RT018 and smz′ /
QX239, was the dominant genotype, followed by
RT014/ST2, RT002/ST8, and RT369/ST81 [12,14].
ST17 was also the predominant genotype in South
Korea, showing high resistance to clindamycin and
moxiﬂoxacin [12,18]. However, in general, the molecular characteristics and antimicrobial resistances of
C. diﬃcile strains circulating in patients with CDI in
the Asia-Paciﬁc region have not been well-described,
and diﬀerences between HA- and CA-CDI in the
Asia-Paciﬁc region are still unclear.
Therefore, to improve our understanding of CDI
epidemiology in the Asia-Paciﬁc region, we conducted
a multicenter retrospective study at seven clinical sites
and one comparative clinical site to analyze diﬀerences
in molecular features and antimicrobial resistance patterns of C. diﬃcile isolates and investigate risk factors
associated with HA- and CA-CDI.

Materials and methods
C. diﬃcile isolates
In total, 394 C. diﬃcile isolates were collected from CDI
patients on a purely random basis without selection

between January 2015 and March 2016. Isolates from
Perth, Australia (n = 31); Sydney, Australia (n = 54);
Busan, South Korea (n = 50); Singapore (n = 29);
Fukuoka, Japan (n = 70); and Hong Kong, China (n
= 50) were sent to our laboratory in transport medium
for anaerobes. A total of 60 isolates were from
New York, USA for the purpose of comparison. Fifty
isolates were cultured from fecal samples collected
from CDI patients in Hangzhou, China, as previous
assays reported [16]. All isolates were recovered on
cefoxitin-cycloserine fructose agar plates (Oxoid,
Basingstoke, United Kingdom) incubated for 48 h at
37°C in an anaerobic chamber with GENbag Anaer
(bioMérieux, Marcy l’Etoile, France). Six control
strains, including ATCC 43255 (RT087), ATCC
BAA-1870 (ST1, RT027), and ATCC BAA-1801
(RT010) were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA).
Collection of clinical data
A standardized questionnaire was completed for each
CDI patient at eight of the clinical sites, excluding
Hong Kong and Singapore, to record sex, age, CDI
type, CDI stage, antimicrobial treatment within the
prior 8 weeks, and biochemical examinations, including white blood cells (WBCs), neutrophils, serum albumin, and creatinine, with cutoﬀ values according to
standard values [19]. Patients with diarrhea induced
by other pathogens were excluded and HA- and
CA-CDI were deﬁned on the basis of the Society for
Healthcare Epidemiology of America and the Infectious Diseases Society of America guidelines [3,20].
Ethical approval for C. diﬃcile isolate and clinical
data collection was received from the Institutional
Review Boards for each respective site. This study
was approved by the Ethics Committee of Zhejiang
Provincial Center for Disease Control and Prevention.
Detection of C. diﬃcile toxin genes
Bacterial genomic DNA of C. diﬃcile isolates and reference C. diﬃcile strains (ATCC 43255, BAA-1870, and
BAA-1801) were prepared using a DNeasy Blood &
Tissue kit (Qiagen Inc., Valencia, CA, USA) according
to the manufacturer’s protocol. The housekeeping gene
tpi, toxin genes tcdA (toxin A) and tcdB (toxin B), and
binary toxin genes cdtA and cdtB were detected by
using a conventional PCR assay with the primer
sequences as previously described [21,22]. The PCR
amplicon sizes of cdtA and cdtB genes were 221-bp
and 262-bp, respectively [21]. The tcdA primers
ampliﬁed a 369-bp amplicon for toxin A-positive/Bpositive (A+B+) strains and a 110-bp amplicon for
toxin A-negative/B-positive (A−B+) strains [22]. After
ampliﬁcation, the PCR products were analyzed by
agarose gel electrophoresis. A reference C. diﬃcile
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strain (ATCC 43255) was used as a positive control for
tcdA and tcdB and negative control for the binary toxin
genes. C. diﬃcile ATCC BAA-1870 was used as a positive control for the binary toxin genes, and C. diﬃcile
ATCC BAA-1801 was chosen as a negative control
for tcdA and tcdB and the binary toxin genes. A
blank, and positive and negative controls were examined in parallel for each test.
Multilocus sequence typing (MLST)
Seven housekeeping genes (adk, atpA, dxr, glyA, recA,
sodA and tpi) were selected, and MLST was performed
as previously described [22]. PCR products were
sequenced commercially by Sangon Biotech Co., Ltd.
(Shanghai, China). Data for C. diﬃcile alleles were
deposited to determine STs in a public C. diﬃcile
MLST database (accessible at http://pubmlst.org/
cdiﬃcile).
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed by
using the agar dilution assay described by the Clinical
and Laboratory Standards Institute in 2017 [23]. All
isolates were subcultured on 5% Columbia blood agar
(Oxoid, UK) and incubated for 48 h anaerobically at
37°C. After adjusting the turbidity to a 0.5 McFarland
standard, aliquots (approximately 1 μL) of the cultures
was spotted onto 1.2% Brucella agar (containing 5%
lysed deﬁber sheep blood, 0.005‰ hemin, and 0.1%
vitamin K1) plus antimicrobials at a given concentration using a multipoint inoculator and incubated
anaerobically at 37°C for 48 h. The antimicrobials
tested were as follows: piperacillin-tazobactam (PIPTAZ), metronidazole, moxiﬂoxacin, clindamycin,
tetracycline, fusidic acid, vancomycin, rifampicin, erythromycin, ciproﬂoxacin, gatiﬂoxacin, and levoﬂoxacin. Interpretation of the minimal inhibitory
concentration (MIC) results was based on previous
studies [16]. Recommended control strains of Bacteroides fragilis (ATCC 25285) and C. diﬃcile (ATCC
700057) were utilized. The C. diﬃcile isolates resistant
to three antimicrobial classes was deﬁned as multidrug
resistance (MDR) according as previously described
[23].
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the diﬀerences among groups, and results with P values
of less than 0.05 were considered statistically
signiﬁcant.

Results
Analysis of clinical data at six sites
Clinical information was obtained for 315 patients with
CDI at six clinical sites, excluding Hong Kong and Singapore. All clinical data were analyzed and compared
among diﬀerent clinical sites (Table 1). The following
parameters were found to be signiﬁcantly correlated
with the presence of CDI among all six sites: age,
CDI type, fever higher than 38.3°C, neutrophils over
70%, serum albumin less than 35 g/L, creatinine
more than 111 μM, and antimicrobial use within the
prior 8 weeks (Table 1). No signiﬁcant diﬀerences
were found in WBCs, and the proportion of WBCs
(cells × 109/L) of more than 10 at all sites was less
than 50% (range: 26.7–44.3%). The mean age of
patients with CDI was signiﬁcantly younger in Hangzhou than in Busan (t = 5.19, P < 0.001), Fukuoka
(Z = −5.18, P < 0.001), and New York (Z = −3.11, P <
0.001) and tended to be younger in Perth (t = 1.63,
P = 0.107) and Sydney (Z = −1.67, P = 0.095). The proportions of HA-CDI were greater among older patients
in Fukuoka and Hangzhou than in Busan (χ 2 = 11.33,
P = 0.001), New York (χ 2 = 16.46, P < 0.001), Perth
(χ 2 = 18.55, P < 0.001), and Sydney (χ 2 = 20.36, P <
0.001). The proportions of patients with CDI having
a fever of higher than 38.3°C were signiﬁcantly in
Hangzhou and Fukuoka than in New York and Perth
(χ 2 = 13.93, P = 0.001). Only 8.6% of patients with
CDI from Fukuoka had over 70% neutrophils, which
was signiﬁcantly lower than those from the other ﬁve
sites (χ 2 = 18.69–96.63, P < 0.001). The proportions of
patients with CDI having serum albumin levels less
than 35 g/L were much higher in Busan and Fukuoka
than in the other four sites (χ 2 = 33.49–86.32, P <
0.001). Furthermore, only 12.0% and 11.1% of patients
with CDI had a history of antimicrobial treatment
within the prior 8 weeks for cases occurring in Busan
and Sydney; these values were much lower than those
from other sites (χ 2 = 21.61–91.67, P < 0.001).
Antimicrobial susceptibility analysis

Data analysis
Data were analyzed using Statistical Package for Social
Sciences (SPSS, Chicago, IL, USA) version 22.0. Chisquare and Fisher’s exact tests were used to analyze
correlations among clinical characteristics, toxin gene
proﬁles, MLST types and antimicrobial susceptibility
proﬁles of C. diﬃcile isolates. The t-test and nonparametric statistics were used to compare diﬀerences in
ages among all sites. P values were calculated to assess

The antimicrobial resistance patterns of 394 C. diﬃcile
isolates are presented in Table S1. Antimicrobial patterns were signiﬁcantly diﬀerent among eight clinical
sites (χ 2 = 325.64, P < 0.001). All isolates were susceptible to vancomycin and metronidazole, with MIC
values of less than 0.5 and 2 μg/mL, respectively. No
isolates were resistant to PIP-TAZ in Busan,
New York, Singapore and Sydney. The rates of rifampin resistance were much lower than those of other
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Table 1. Clinical information of CDI patients.
Characteristics
Gender, male (%)
Age, Mean (range)
CDI type, HA-CDI (%)
CDI stage, Primary CDI (%)
Fever, ≥38.3°C (%)
WBC (cells ×109/L), >10 (%)
Neutrophils, >70% (%)
Serum albumin (g/L), <35 (%)
Creatinine (umol/L), >111 (%)
Antimicrobial used within 8 weeks, Yes (%)
a

Busan
(n = 50)

Fukuoka
(n = 70)

Hangzhou
(n = 50)

New York
(n = 60)

Perth
(n = 31)

Sydney
(n = 54)

29 (58.0%)
67 (22–87)
32 (64.0%)
50 (100%)
–
22 (44.0%)
21 (42.0%)
42 (84.0%)
7 (14.0%)
6 (12.0%)

46 (65.7%)
67.1 (1–94)
64 (91.4%)
70 (100%)
14 (20.0%)
31 (44.3%)
6 (8.6%)
62 (88.6%)
21 (30.0%)
59 (84.3)

32 (64.0%)
53.4 (26–81)
40 (80.0%)
50 (100%)
11 (22.0%)
19 (38.0%)
20 (40.0%)
22 (44.0%)
5 (10.0%)
30 (60.0%)

27 (45.0%)
59.6 (1–85)
36 (60.0%)
53 (88.3%)
1 (1.7%)
16 (26.7%)
57 (95.0%)
14 (23.3%)
0
26 (43.3%)

16 (51.6%)
58.3 (24–88)
16 (51.6%)
25 (80.6%)
2 (6.5%)
13 (41.9%)
–
0
10 (32.3%)
19 (61.3%)

23 (42.6%)
66.2 (0.6–93)
30 (55.6%)
50 (92.6%)
–
22 (40.7%)
27 (50.0%)
16 (29.6%)
14 (25.9%)
6 (11.1%)

Analysis results
χ2

P value

10.99
36.96
31.20
Fa
14.34
5.38
98.83
122.51
29.16
97.95

0.052
<0.001
<0.001
<0.001
0.002
0.371
<0.001
<0.001
<0.001
<0.001

F: Fisher’s exact test.

antimicrobials in the Asia-Paciﬁc region. The antimicrobial resistance rates were compared among three
continents as follows. The rates of fusidic acid resistance in New York, Sydney, and Perth were signiﬁcantly
higher than those in sites from Asia (χ 2 = 125.03, P <
0.001). However, the rates of moxiﬂoxacin, tetracycline, and erythromycin resistance in C. diﬃcile isolates from the three above sites were much lower than
those from other sites (χ 2 = 26.46–63.81, P < 0.001).
The proportions of isolates resistant to gatiﬂoxacin in
two sites from Australia were signiﬁcantly lower than
those in other sites (χ 2 = 52.84, P < 0.001). Notably,
186 (47.2%) of these isolates were MDR, although the
rate of MDR was signiﬁcantly lower in isolates from
three sites in the USA and Australia than those from
sites in Asia (χ 2 = 51.35, P < 0.001).
Genotyping analysis of C. diﬃcile isolates
Of the 394 C. diﬃcile isolates, 337 (85.5%) were positive
for both tcdA and tcdB and negative for both cdtA and
cdtB (A+B+CDT−), 48 (12.2%) including one from
New York, four from two sites in Australia, and 43
from other sites in Asia tested negative for tcdA and
positive for tcdB without cdtA and cdtB (A−B+
CDT−), and nine (2.3%) including two from Australia,
two from sites in Asia, and ﬁve from New York were
positive for tcdA, tcdB, cdtA, and cdtB (A+B+CDT+).

The MLST analysis identiﬁed 68 diﬀerent STs, and
ﬁve C. diﬃcile isolates were not typed because several
housekeeping genes were not ampliﬁed. ST2 (n = 12,
4.8%), ST3 (n = 15, 6.0%), ST8 (n = 21, 8.4%), ST17
(n = 42, 16.9%), ST35 (n = 14, 5.6%), ST37 (n = 20,
8.0%), ST54 (n = 18, 7.2%), ST63 (n = 9, 3.6%), and
ST81 (n = 17, 6.8%) were the dominant genotypes in
Asia. However, the diﬀerent distribution of STs was
found in USA and Australia as follows. ST2 (n = 7,
11.7%) and ST42 (n = 11, 18.3%) were dominant STs
in New York. ST2 (n = 19, 22.4%) and ST8 (n = 10,
11.8%) were dominant genotypes in two sites in Australia. There was a signiﬁcant diﬀerence on the distribution of STs among three above regions (χ 2 = 24.73,
P < 0.001).
Diﬀerent sites had a variety of STs, exhibiting varying distributions (Figure 1). Two isolates from
New York and Sydney were ST11. The CDT-positive
isolates included three ST1 isolates (one from Hong
Kong, two from New York), three ST41 isolates (one
from New York, two from Perth), and three other
STs (ST32 and ST67 from New York, ST95 from Singapore). The dominant genotypes between sites varied
signiﬁcantly, with ST17 in Fukuoka (n = 13, 18.6%)
and Busan (n = 28, 56.0%); ST2 in New York as
above, Sydney (n = 11, 20.4%) and Perth (n = 8,
25.8%); ST8 in Hong Kong (n = 10, 20.0%), Fukuoka
(n = 9, 12.8%), and Sydney (n = 7, 13.0%); ST63 in

Figure 1. Distribution of STs at each site in this study. A: The seven sites are distributed in the Asia-Paciﬁc region, and one comparative clinical site is New York, USA. B: Each site had various STs with diﬀerent types of distribution. The major STs of C. diﬃcile
were labelled with diﬀerent colours.
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Singapore (n = 9, 31.0%); ST42 in New York as above;
and ST3 (n = 10, 20.0%), ST37 (n = 13, 26.0%), and
ST54 (n = 10, 20.0%) in Hangzhou.

Comparison of clinical characteristics between
HA- and CA-CDI
Of 315 patients with CDI with available clinical information, one patient from New York belonged to neither
HA-CDI nor CA-CDI, exhibiting onset between 4 and
12 weeks after the ﬁnal discharge, as previously published guidelines [3,20]. Clinical characteristics and genotypes were compared between HA- and CA-CDI for
255 patients in the Asia-Paciﬁc region with retrievable
C. diﬃcile isolates (Table 2), the 59 patients from
New York were also analyzed (data not shown). In comparison with CA-CDI, HA-CDI had a signiﬁcantly
higher frequency of age over 65 years and more frequent
antimicrobial use. Moreover, patients with HA-CDI had
a greater frequency of isolates with A−B+ genotype than
patients with CA-CDI, although there were no signiﬁcant diﬀerences in the distributions of STs between
these groups (Table 2). Higher resistance rates to
gatiﬂoxacin, tetracycline, and erythromycin was
observed in patients with HA-CDI (χ 2 = 4.76–7.89, p =

0.005–0.029). C. diﬃcile isolates related to CA-CDI
had much higher rates of fusidic acid resistance than isolates related to HA-CDI in the Asia-Paciﬁc region (Table
2) and New York (data not shown). Furthermore,
C. diﬃcile isolates associated with CA-CDI had signiﬁcantly higher rates of moxiﬂoxacin resistance than
isolates with HA-CDI in New York (Fisher’s exact test,
p = 0.029) (data not shown).

Phylogenetic analysis based on MLST
The genetic diversity and phylogenetic relationships of
the 394 isolates were analyzed on the basis of MLST
patterns. The minimum spanning tree (MST) was generated as shown in Figure 2. In total, 68 STs were distributed in the phylogenetic tree. Five major clonal
complexes (CC) were artiﬁcially divided based on the
discriminating ability and typeability of MLST[24,25]
according the certain assay, among which more than
two allelic diﬀerences existed between each of the two
clusters, and there were fewer than two allelic diﬀerences between STs in the same cluster. The detailed
STs were shown in each CC in Figure 2. The STs in
CC1, CC2, and CC4 were distributed from various
regions; all STs in CC3 belonged to A−B+ and mainly

Table 2. Diﬀerences of clinical characteristics, genotypes and antimicrobial resistance between HA-CDI
and CA-CDI.
No. (%) of CDI patients
Characteristics
Gender, male (%)
Age, Mean (range)
Years of age, ≥65 (%)
Fever, ≥38.3°C
Primary CDI (%)
Antimicrobials used within 8 weeks (%)
Toxin gene pattern
A+B+ (n = 216)
A+B+CDT+ (n = 2)
A+B+CDT− (n = 214)
MLST type
ST2 (n = 27)
ST3 (n = 15)
ST8 (n = 21)
ST17 (n = 43)
ST35 (n = 12)
ST54 (n = 12)
Other STs (n = 86)
A−B+(n = 39)
MLST type
ST37 (n = 19)
ST81 (n = 17)
Other STs (n = 3)
Antimicrobial resistance rateb
Fusidic acid, non-S (%)
Ciproﬂoxacin, non-S (%)
PIP-TAZ, non-S (%)
Rifampicin, non-S (%)
Moxiﬂoxacin, non-S (%)
Gatiﬂoxacin, non-S (%)
Clindamycin, non-S (%)
Levoﬂoxacin, non-S (%)
Tetracycline, non-S (%)
Erythromycin, non-S (%)
a

F: Fisher’s exact test; b S: susceptible.
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HA-CDI
(n = 182)

CA-CDI
(n = 73)

111 (61.0%)
63.5 (0.8–94)
87 (47.8%)
22 (12.1%)
175 (96.2%)
93 (51.1%)

35 (47.9%)
61.0 (0.6–93)
22 (30.1%)
5 (6.8%)
66 (90.4%)
21 (28.8%)

148 (81.3%)
1 (0.5%)
147 (80.8%)

68 (93.2%)
1 (1.4%)
67 (91.8%)

12 (6.6%)
10 (5.5%)
17 (9.3%)
32 (17.6%)
10 (5.5%)
8 (4.4%)
59 (32.4%)
34 (18.7%)

15 (20.5%)
5 (6.8%)
4 (5.5%)
11 (15.1%)
2 (2.8%)
4 (5.5%)
27 (37.0%)
5 (6.8%)

16 (8.8%)
15 (8.2%)
3 (1.6%)
101 (55.5%)
173 (95.1%)
12 (6.6%)
11 (6.0%)
72 (39.6%)
82 (45.1%)
157 (86.3%)
170 (93.4%)
48 (26.4%)
99 (54.4%)

Analysis results
χ2

P value

3.62

0.057

6.64
1.51
2.30
10.51

0.010
0.219
0.130
0.001

5.63
Fa

0.018
0.532

3 (4.1%)
2 (2.7%)
0

F
10.72
0.01
1.03
0.23
0.37
<0.01
0.49
5.63
F
1.66
1.73
F

0.119
0.001
0.904
0.311
0.628
0.541
0.966
0.485
0.018
1.000
0.198
0.189
0.560

54 (73.9%)
71 (97.3%)
4 (5.5%)
4 (5.5%)
20 (27.4%)
19 (26.0%)
65 (89.0%)
67 (91.8%)
10 (13.7%)
26 (35.6%)

5.13
0.20
<0.01
<0.01
3.34
7.89
0.36
0.21
4.76
7.35

0.024
0.658
0.963
1.000
0.068
0.005
0.550
0.647
0.029
0.007
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Figure 2. Relationship of all C. diﬃcile isolates based on MLST by MST. The number in the circle shows the ST type, and the size of
circle corresponds the total number of C. diﬃcile isolates belonging to this ST. The number of allelic diﬀerences between STs is
showed on the branches. Nodes are connected by a dashed line if the allelic diﬀerence is over two alleles. Diﬀerent colours correspond to diﬀerent sites. A: The MST of C. diﬃcile isolates in the study, B: A part of MST-CC1 including ST34, 35, 44, 54, 58, 95, and
357; C: A part of MST-CC2 including ST2, 3, 4, 8, 13, 14, 16, 17, 18, 28, 29, 32, 33, 42, 48, 49, 53, 66, 83, 92, 101, 102, 110, 183, 203, and
322; D: A part of MST-CC3 including ST37, 81, and 219; E: A part of MST-CC4 including ST43, 104, 129, 152, 235, and 239; F: A part of
MST-CC5 including ST1, 41, 67, and 362.

came from Hangzhou and Fukuoka (69.0%, 29/42);
and STs in CC4 were predominantly from New York
(62.5%, 5/8). The remaining STs were distributed outside of the ﬁve major CCs (Figure 2).
Correlations between major genotypes and
antimicrobial resistance patterns
Correlations between antimicrobial resistance and
dominant genotypes are shown in Table S2. The antimicrobial patterns for A+B+ isolates were signiﬁcantly
diﬀerent from those of A−B+ isolates (χ 2 = 35.11, P <
0.001). Eleven PIP-TAZ-resistant isolates were distributed in diﬀerent STs, and only one isolate was found in
ST37 (A−B+). All ST81 isolates were susceptible to PIPTAZ and rifampin, but presented higher resistance
rates for other antimicrobials than those of other STs.
ST37 isolates possessed a higher rifampin resistance
rate than other STs (Fisher’s exact test, P < 0.001).
ST2 isolates had lower resistance rates to moxiﬂoxacin,
tetracycline, and erythromycin than other antimicrobials. ST37 and ST17 isolates showed lower fusidic
acid resistance rates than other STs, except ST3 and
ST54 (χ 2 = 10.35–53.25, P < 0.001). In general, the
resistance patterns for most antimicrobials were signiﬁcantly diﬀerent among predominant STs (χ 2 =
53.25–109.05, P < 0.001).

Correlations between major CCs and
antimicrobial resistance patterns
The distributions of antimicrobial resistance patterns
in ﬁve major CCs are shown in Table 3. The rates of
resistance to fusidic acid, ciproﬂoxacin, and PIP-TAZ
in CC3 were lower than those in other CCs, although
there were no signiﬁcant diﬀerences. However,
C. diﬃcile isolates had signiﬁcantly higher rates of
resistance to rifampin, ﬂuoroquinolone, tetracycline,
and erythromycin in CC3 in the A−B+ group than in
other CCs in the A+B+ group (χ 2 = 36.84–49.29, P <
0.001). No isolates resistant to PIP-TAZ, metronidazole, rifampin, moxiﬂoxacin, vancomycin, tetracycline,
and erythromycin were found in CC4, in which the rate
of MDR was also signiﬁcantly lower than in other CCs
(Fisher’s exact test, P = 0.001).

Discussion
In recent years, an increasing number of studies has
evaluated CDI epidemiology in Asia [12,26]. These
have suggested that CDI is a very much under-recognized problem in Asia owing to poor clinical awareness
among physicians [12]. To date, small-scale data have
described CDI epidemiology within diﬀerent countries
in Asia. However, the molecular characteristics and
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Table 3. Diﬀerence of antimicrobial resistance patterns in ﬁve clonal complexes of C. diﬃcile isolates.
Clonal complexes based on MLST type (No. [%] of non-susceptible isolates)
Antimicrobial

CC1 (n = 52)

Fusidic acid
30 (57.7%)
Ciproﬂoxacin
51 (98.1%)
PIP-TAZ
2 (3.8%)
Metronidazole
0
Rifampin
4 (7.7%)
Moxiﬂoxacin
5 (9.6%)
Gatiﬂoxacin
6 (11.5%)
Vancomycin
0
Clindamycin
48 (92.3%)
Levoﬂoxacin
47 (90.4%)
Tetracycline
23 (44.2%)
Erythromycin
35 (67.3%)
MDR
51 (98.1%)
a
F: Fisher’s exact test; bN/A: not applicable.

Analysis results

CC2 (n = 204)

CC3 (n = 42)

CC4 (n = 15)

CC5 (n = 8)

χ2

P value

121 (59.3%)
199 (97.5%)
12 (5.9%)
0
4 (2.0%)
75 (36.8%)
92 (45.1%)
0
186 (91.2%)
196 (96.1%)
19 (9.3%)
80 (39.2%)
194 (95.1%)

21 (50.0%)
40 (95.2%)
1 (2.4%)
0
7 (16.7%)
26 (61.9%)
31 (73.8%)
0
36 (85.7%)
39 (92.9%)
23 (54.8%)
35 (83.3%)
38 (90.5%)

10 (66.7%)
15 (100%)
0
0
0
0
4 (26.7%)
0
14 (93.3%)
15 (100%)
0
0
10 (66.7%)

6 (75.0%)
8 (100%)
0
0
1 (12.5%)
3 (37.5%)
4 (50.0%)
0
5 (62.5%)
8 (100%)
1 (12.5%)
3 (37.5%)
6 (75.0%)

2.63
Fa
F
N/Ab
F
36.84
39.49
N/Ab
F
F
67.92
49.29
F

0.622
0.806
0.908
N/A
0.001
<0.001
<0.001
N/A
0.115
0.369
<0.001
<0.001
0.001

antimicrobial resistances of C. diﬃcile isolates in the
Asia-Paciﬁc region have not been fully elucidated,
despite the large population in this region. In this retrospective study, we found that there were signiﬁcant
diﬀerences in ST distributions and antimicrobial resistance patterns among the seven sites in the Asia-Paciﬁc
region and New York. Patients with HA-CDI tended to
be older, have more frequent antimicrobial use, exhibit
lower infection rates with A+B+ genotypes, and show
higher resistance to gatiﬂoxacin, tetracycline, and erythromycin than patients with CA-CDI in Asia-Paciﬁc
region but not in New York. Five major CCs correlated
with unique antimicrobial resistances, and the rifampin, ﬂuoroquinolone, tetracycline, and erythromycin
resistance rates in the A−B+ cluster were signiﬁcantly
higher than those in the A+B+ group.
Interestingly, a diﬀerent distribution of STs was
found in diﬀerent regions located in separate continents including Australia, USA, and Asian countries.
Moreover, speciﬁc STs were dominant in neighbouring
regions. ST17 was a dominant genotype in Fukuoka
and Busan, both of which were located in Northeast
Asia. Sydney and Perth, two major cities in Australia,
had the same dominant genotype, ST2. Similar data
has been reported previously [12,18]. In addition,
diﬀerent sites had their own dominant genotypes, i.e.
ST3, ST37, and ST54 in Hangzhou; ST63 in Singapore;
ST8 in Hong Kong; and ST42 in New York. Additionally, these sites showed diﬀerent antimicrobial resistance patterns.
CDI epidemiology in America has been changing in
recent years. ST42 has replaced ST1 as one of the most
frequent types in the USA [27], and ST42 has become
one of the most common genotype in Brazil [28]. However, CDI epidemiology in China presented stable, and
ST3, ST37, and ST54 have been being dominant genotypes in diﬀerent regions in China [15,16]. Consequently, our study demonstrated that multiple
C. diﬃcile genotypes are circulating in the AsiaPaciﬁc region and exhibit unique molecular characteristics at each site. C. diﬃcile isolates with the same STs
may be transmitted between diﬀerent regions through

food trade and travel in the Asia-Paciﬁc region as previously reported [26]. Further studies focusing on
analysis of whole-genome sequences combined with
epidemiological data are required to investigate genetic
relationship between diﬀerent sites for the same STs.
There were statistically signiﬁcant diﬀerences in antimicrobial resistance patterns not only among diﬀerent
sites but also among the major STs identiﬁed in our
study. Our previous study also showed that the major
genotypes were associated with signiﬁcantly diﬀerent
antimicrobial resistance patterns in comparison with
other genotypes in C. diﬃcile in Eastern China [16].
Antimicrobial resistance mechanisms in C. diﬃcile
have been investigated and associated with genes and
gene mutations [29]. Diﬀerent STs obtained various
mobile genetic elements containing diﬀerent antimicrobial resistance-related genes at the diﬀerent time in the
course of genome evolution, maybe resulting in signiﬁcant diﬀerences in antimicrobial resistance patterns
among the STs [8,30]. Although extremely high rates
of resistance to clindamycin, and levoﬂoxacin were
observed at all sites, New York, Sydney, and Perth
showed lower rates for moxiﬂoxacin, tetracycline, and
erythromycin resistance than isolates from Asian
locations. The low antimicrobial resistance rates in
these sites could have several explanations. In Australia,
the use of ﬂuoroquinolones has historically been regulated and restricted in both humans and food-producing animals [31]. Access to antimicrobials for clinical
use can only be obtained through physician prescription
and antimicrobials are not available for over the counter
purchase. Furthermore, antimicrobial stewardship programmes were established during the early stages of epidemic outbreaks and strictly implemented in the USA
and Australia, respectively [32–35]. As inappropriate
use of antimicrobials has been a major concern in recent
years in Asia, a stewardship approach to antimicrobial
use in humans and animals, when combined with
enhanced infection control, may help to decrease antimicrobial resistance rates in the future.
Even though some clinical parameters were found to
be signiﬁcantly correlated with CDI, small numbers of
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samples might lead to possible bias in our data analysis
results between sites. Thus, more clinical samples
should be collected to investigate diﬀerences on clinical
parameters of CDI patients among diﬀerent countries
in the Asia-Paciﬁc region. Notably, we found that the
mean age of patients with CDI in Hangzhou was
younger than that in other sites despite small numbers
of samples involved in this study. Similar results have
been reported in the other studies of CDI epidemiology
in China [16,36,37]. Interestingly, we also found the
high rates of HA-CDI with over 50% in each site,
and HA-CDI tended to be older patients with more frequent antimicrobial use. Furthermore, C. diﬃcile A−B+
genotypes infected more patients with HA-CDI, with
higher rates of gatiﬂoxacin, tetracycline, and erythromycin resistance, than patients with CA-CDI in the
Asia-Paciﬁc region. These above molecular characteristics of CDI were obviously diﬀerent from those in
New York. To the best of our knowledge, this was
the ﬁrst study elucidating the diﬀerences between
patients with HA- and CA-CDI in the Asia-Paciﬁc
region and diﬀerences on molecular characteristics of
CDI in between the Asia-Paciﬁc region and the other
region. While healthcare associated acquisition has
been the primary pathway for CDI increasing incidence densities in the USA [38], recent data indicated
that over 40% of CDIs in the USA were communityassociated [6,39]; in Europe, 76.4% of CDI cases were
healthcare-associated [40]. However, the main transmission pathway of CDI is still unknown in Asia, particularly China. Large-scale CDI epidemiological
investigations are required to clarify the main route
of transmission for CDI.
Our study had several limitations. First, all
C. diﬃcile isolates used in this study were not collected
at the same period. CDI epidemiology is dynamically
changing; thus, the distributions of genotypes and antimicrobial resistance patterns may have shown slight
bias during data analysis. Second, this was a retrospective study involving relatively small numbers of cases
recruited from each site. There were no detailed set
inclusion or exclusion criteria thereby potentially
resulting in a possible bias in our data analysis results
between sites. Third, as there is a paucity of data on
clinical outcomes in CDI patients, the diﬀerences of
clinical outcomes among diﬀerent regions and among
CDIs with diﬀerent molecular genotypes were not analyzed. Fourth, our study lacked some sites in Asian
countries and did not cover the whole Asia-Paciﬁc
region. Thus, further investigations are required to
clarify the diﬀerences of clinical outcomes induced by
various genotypes of C. diﬃcile in diﬀerent regions,
and conﬁrm the molecular characteristics of
C. diﬃcile isolates in the Asia-Paciﬁc region.
In conclusion, this was the ﬁrst multicenter retrospective study in the Asia-Paciﬁc region evaluating
diﬀerences in the molecular features and antimicrobial

resistance patterns of C. diﬃcile isolates and investigating risk factors in patients with HA- and CA-CDI.
Multiple C. diﬃcile genotypes with varied antimicrobial resistance patterns have been circulating in the
Asia-Paciﬁc region. A−B+ isolates in older people and
individuals with prior antimicrobial use were associated with HA-CDI. Consequently, CDI has a major
presence in the Asia-Paciﬁc region, and it is necessary
to initiate CDI surveillance through international collaboration and implement antimicrobial stewardship
programmes in order to prevent and control CDI.
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